IRIS Accounts Production v24.3.0.553 12769240 Board of Directors 1.1.23 31.12.23 31.12.23 14.11.24 false true false false true false Auditors Opinion iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh127692402022-12-31127692402023-12-31127692402023-01-012023-12-31127692402021-12-31127692402022-01-012022-12-31127692402022-12-3112769240ns15:EnglandWales2023-01-012023-12-3112769240ns14:PoundSterling2023-01-012023-12-3112769240ns10:Director12023-01-012023-12-3112769240ns10:PrivateLimitedCompanyLtd2023-01-012023-12-3112769240ns10:SmallEntities2023-01-012023-12-3112769240ns10:Audited2023-01-012023-12-3112769240ns10:SmallCompaniesRegimeForDirectorsReport2023-01-012023-12-3112769240ns10:SmallCompaniesRegimeForAccounts2023-01-012023-12-3112769240ns10:FullAccounts2023-01-012023-12-3112769240ns10:Director22023-01-012023-12-3112769240ns10:RegisteredOffice2023-01-012023-12-3112769240ns5:CurrentFinancialInstruments2023-12-3112769240ns5:CurrentFinancialInstruments2022-12-3112769240ns5:ShareCapital2023-12-3112769240ns5:ShareCapital2022-12-3112769240ns5:RetainedEarningsAccumulatedLosses2023-12-3112769240ns5:RetainedEarningsAccumulatedLosses2022-12-3112769240ns5:PlantMachinery2022-12-3112769240ns5:PlantMachinery2023-01-012023-12-3112769240ns5:PlantMachinery2023-12-3112769240ns5:PlantMachinery2022-12-3112769240ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-12-3112769240ns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-12-31
REGISTERED NUMBER: 12769240 (England and Wales)















Financial Statements for the Year Ended 31 December 2023

for

Central Pharma Cell and Gene Therapy Ltd

Central Pharma Cell and Gene Therapy Ltd (Registered number: 12769240)






Contents of the Financial Statements
for the Year Ended 31 December 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


Central Pharma Cell and Gene Therapy Ltd

Company Information
for the Year Ended 31 December 2023







DIRECTORS: Mrs K Y Nichol
Mr A J Smit





REGISTERED OFFICE: Central Pharma
Caxton Road
Elm Farm Ind Estate
Bedford
Bedfordshire
MK41 0HT





REGISTERED NUMBER: 12769240 (England and Wales)





AUDITORS: WP Audit Limited
Statutory Auditors
TOR
Saint-Cloud Way
Maidenhead
Berkshire
SL6 8BN

Central Pharma Cell and Gene Therapy Ltd (Registered number: 12769240)

Balance Sheet
31 December 2023

31.12.23 31.12.22
Notes £    £   
FIXED ASSETS
Tangible assets 4 39,496 44,510

CURRENT ASSETS
Debtors 5 189,897 50,352
Cash at bank 62,288 9,945
252,185 60,297
CREDITORS
Amounts falling due within one year 6 (2,166,467 ) (1,980,971 )
NET CURRENT LIABILITIES (1,914,282 ) (1,920,674 )
TOTAL ASSETS LESS CURRENT LIABILITIES (1,874,786 ) (1,876,164 )

CAPITAL AND RESERVES
Called up share capital 1 1
Retained earnings (1,874,787 ) (1,876,165 )
(1,874,786 ) (1,876,164 )

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 17 October 2024 and were signed on its behalf by:





Mrs K Y Nichol - Director


Central Pharma Cell and Gene Therapy Ltd (Registered number: 12769240)

Notes to the Financial Statements
for the Year Ended 31 December 2023

1. STATUTORY INFORMATION

Central Pharma Cell and Gene Therapy Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The accounts are prepared on the going concern basis. The company is part of the Central Pharma Contract Holdings Limited group of companies which specialise in packing, warehousing and logistics. The group has invested significant resources into establishing its offering to the cell and gene therapy sector and the directors consider that there are significant opportunities for the company as a result of the investment made. The directors consider that the company can expect continued support from the group to successfully convert the opportunities available to it and on that basis the directors consider that the company has sufficient facilities available to it for the foreseeable future, that is at least 12 months from the date of approval of these accounts.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Significant judgements and estimates
In the application of the company's accounting policies the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The company does not make significant estimates and assumptions concerning the future which affect the presentation in the accounts.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life'

Computer equipment - 33% on a straight line basis

Plant and machinery - 20% on a straight line basis < £50K and 10% on straight line basis > £50K

Fixtures and fittings - 20% on a straight line basis

Financial instruments
Basic financial instruments are recognised at amortised cost using the effective interest method, except for investments in non-convertible preference and non-puttable preference and ordinary shares, which are measured at fair value, with changes recognised in profit or loss. Derivative financial instruments are initially recorded at cost and thereafter at fair value, with changes recognised in profit and loss.


Central Pharma Cell and Gene Therapy Ltd (Registered number: 12769240)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2023

2. ACCOUNTING POLICIES - continued
Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Bad debt provisions
Provisions are estimated by the company in respect of specific debts based upon the age of the debt and knowledge of known issues.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 3 (2022 - 5 ) .

Central Pharma Cell and Gene Therapy Ltd (Registered number: 12769240)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2023

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 January 2023 61,958
Additions 11,303
At 31 December 2023 73,261
DEPRECIATION
At 1 January 2023 17,448
Charge for year 16,317
At 31 December 2023 33,765
NET BOOK VALUE
At 31 December 2023 39,496
At 31 December 2022 44,510

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.23 31.12.22
£    £   
Trade debtors 161,152 -
Other debtors 28,745 50,352
189,897 50,352

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.23 31.12.22
£    £   
Trade creditors 335,141 199,216
Amounts owed to group undertakings 1,711,119 1,517,157
Taxation and social security 30,370 4,486
Other creditors 89,837 260,112
2,166,467 1,980,971

7. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Philippa Duckworth BSc FCCA (Senior Statutory Auditor)
for and on behalf of WP Audit Limited

8. ULTIMATE CONTROLLING PARTY

The ultimate parent company is Central Pharma Contract Holdings Limited. The ultimate parent company consolidates the results of the company. There is no single ultimate controlling party.